It has been demonstrated that the IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing can be abrogated by the IL6R blocking antibody tocilizumab in breast cancer41. Here, IL6R is linked to neoplasm.